Two‐year outcomes of infants enrolled in the first‐in‐human study of amnion cells for bronchopulmonary dysplasia
Abstract We previously reported on the immediate safety and neonatal outcomes of six premature infants with severe bronchopulmonary dysplasia (BPD) who were administered human amnion epithelial cells (hAECs). One infant died in the neonatal period due to unrelated causes. In this study, we aimed to...
Main Authors: | Atul Malhotra, Rebecca Lim, Joanne C. Mockler, Euan M. Wallace |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Stem Cells Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/sctm.19-0251 |
Similar Items
-
First‐In‐Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia: A Safety Study
by: Rebecca Lim, et al.
Published: (2018-09-01) -
Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant
by: Lidys eRivera, et al.
Published: (2016-03-01) -
Decreased neutrophil levels in bronchopulmonary dysplasia infants
by: Xingchao Li, et al.
Published: (2020-12-01) -
Risk Factors for Tracheobronchomalacia in Preterm Infants With Bronchopulmonary Dysplasia
by: Ya-Ting Su, et al.
Published: (2021-06-01) -
Stem cells as therapeutical option for the treatment of bronchopulmonary dysplasia
by: Dominik Monz, et al.
Published: (2015-12-01)